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External pneumatic compression does not increase
urokinase plasminogen activator after
abdominal surgery
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Tatsuo Uchida, MS,b and Lois A. Killewich, MD, PhD,a Galveston, Tex; and Baltimore, Md
External pneumatic compression (EPC) devices prevent lower extremity deep venous thrombosis (DVT) by reducing
stasis. There is a widely held belief that they also enhance endogenous fibrinolysis; however, recent studies of tissue
plasminogen activator (the primary activator of fibrinolysis) and plasminogen activator inhibitor1 (the primary
inhibitor of fibrinolysis) failed to confirm this. The hypothesis of this study was that EPC devices increase the level of
urokinase plasminogen activator (uPA), a second activator of fibrinolysis. This was a prospective trial in which 44 subjects
who underwent major abdominal surgery were randomized to receive unfractionated heparin injections, thigh-length
sequential EPC devices, or both for DVT prophylaxis. Prophylaxis was begun immediately before surgical incision and
continued until postoperative day 5 or discharge. Venous blood samples were collected from an antecubital vein for
measurement of systemic uPA levels and from the common femoral vein for measurement of regional uPA levels. Samples
were collected the day before surgery, after induction of anesthesia but before surgical incision, and on postoperative days
1, 3, and 5. uPA levels (ng/mL) were measured with an enzyme-linked immunoassay. Baseline uPA levels (0.41 to 0.56
ng/mL; P > .05, analysis of variance with repeated measures) were similar among the three groups. uPA levels did not
change after surgery in systemic or regional blood samples in any group. There were no significant differences in systemic
or regional uPA levels in the groups treated with EPC devices relative to those treated with heparin at any time point (P >
.05, analysis of variance with repeated measures). Enhancement of fibrinolysis with EPC devices remains unproven; the
findings reported here suggest that effective DVT prophylaxis can only be assured when the devices are used in a manner
that reduces venous stasis. (J Vasc Surg 2002;36:917-21.)
External pneumatic compression (EPC) devices are
widely used and highly efficacious in prevention of lower
extremity deep venous thrombosis (DVT) in many patient
populations.1,2 They reduce the incidence rate of lower
extremity DVT by increasing flow velocities in lower ex-
tremity veins, thus reducing the stasis component of Vir-
chow’s triad.3-6
EPC devices have also been thought to increase endo-
genous fibrinolysis, the system by which the body lyses
excess or inappropriately formed thrombus. Early data sup-
ported this belief,7,8 but more recent studies in which
specific fibrinolytic factors were measured have not uni-
formly shown EPC-mediated enhancement. In volunteer
subjects, increased tissue plasminogen activator (tPA; the
main activator of fibrinolysis) and decreased plasminogen
activator inhibitor1 (PAI-1; the main inhibitor of fibri-
nolysis) during pneumatic compression were shown in
some studies9 but not in others.10,11 In subjects undergo-
ing major surgical procedures, no studies have confirmed
enhancement of fibrinolytic activity during pneumatic
compression.12,13
Endogenous fibrinolysis can also be increased through
activation of the protease urokinase plasminogen activator
(uPA), which like tPA cleaves plasminogen to plasmin. uPA
was originally thought to exert its main activity in tissue
remodeling, through wound healing, inflammation, em-
bryogenesis, and tumor cell invasion and migration.14,15
However, recent animal studies suggest that uPA may also
have a physiologically important role in lysis of throm-
bus.16-18 In humans, it is increased after venous stasis19 and
strenuous physical exercise,20 as is the case with tPA. In this
study, the hypothesis was that EPC devices enhance endog-
enous fibrinolysis by increasing the levels of uPA, measured
in the systemic circulation or regionally in the extremity
undergoing pneumatic compression.
METHODS
Subjects and procedures
Forty-four subjects (all male; mean age, 67 years) un-
dergoing major abdominal surgery were randomized to
one of three groups for DVT prophylaxis: 1, unfractionated
heparin injections given subcutaneously at a dose of 5000
units twice a day (HEP); 2, thigh-length sequential pneu-
matic compression devices (EPC; Kendall Health Care,
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Manchester, Mass); or 3, combination of both methods
(HEPEPC). The HEP group constituted the control
group for the study; heparin injections are a standard
method of DVT prophylaxis in subjects undergoing ab-
dominal surgery, and it was not considered ethical to have
a control group in which no DVT prophylaxis was used.
Thigh-length EPC devices were selected because they com-
press the largest volume of lower extremity tissue of any
device and an effect on uPA would therefore be easier to
detect. The surgical procedures that were performed are
listed in the Table; these included 10 abdominal aortic
aneurysm repairs, 24 resections for malignant disease, and
10 miscellaneous laparotomies (nine bowel resections/lysis
of adhesions, one splenectomy). This study was approved
by the Institutional Review Board, and all subjects gave
informed consent before participation.
Ultrasound scans. A venous duplex ultrasound scan
was performed before study enrollment to exclude preex-
isting venous disease, and a second ultrasound scan was
performed on postoperative day 5 or before discharge to
exclude the development of DVT. Subjects with a history
or ultrasound scan evidence of venous thromboembolic
disease (acute or chronic DVT or venous valvular insuffi-
ciency) or a requirement for preoperative or postoperative
systemic anticoagulation therapy were excluded. Ultra-
sound scans were routinely performed from the confluence
of the tibial veins to the iliac veins. Calf veins were scanned
only when other evidence suggestive of DVT was present
on the ultrasound scan, for example, continuous venous
flow. The criteria for an ultrasound scan positive for DVT
(acute or chronic) have been previously reported.21 Venous
valvular insufficiency was defined as valve closure times of
more than 0.5 seconds elicited with manual compression
and Valsalva’s maneuvers in more than one major venous
segment. DVT prophylaxis was initiated in the operating
room after induction of anesthesia and continued until
postoperative day 5 or discharge.
Fibrinolytic measurements. Fibrinolysis was quanti-
fied with measurement of the antigen level of urokinase-
type plasminogen activator (uPA) with an enzyme-linked
immunoassay, IMUBAND uPA ELISA Kit, Product No.
894 (American Diagnostica Inc, Greenwich, Conn). Blood
samples were collected from an antecubital vein for mea-
surement of systemic fibrinolysis and from the common
femoral vein for measurement of regional fibrinolysis. Sam-
ples were collected on the day before surgery, after induc-
tion of anesthesia but before initiation of prophylaxis
(ANES), and on postoperative days 1, 3, and 5. Preopera-
tive samples were collected from an antecubital vein only.
All subjects in the EPC and EPCHEP groups wore EPC
devices on both lower extremities, and all sampling was
performed from the same extremity in each subject. The
choice of extremity was determined randomly. A study
coordinator monitored the devices twice daily to ensure
that they remained on the subject and were functioning.
Devices were always inspected approximately 1 hour before
collection of blood to ensure that uPA levels reflected the
effects of pneumatic compression.
For determination of u-PA level, blood was first col-
lected into 3.8% citrated tubes and maintained at 4° C until
centrifugation at 10,000g for 20 minutes. Platelet-poor
plasma was stored at 80° C until assays were performed.
Statistical analysis. Systemic and regional uPA levels
were analyzed with analysis of variance for a two-factor
experiment with repeated measures on one factor (time).
The two factors were subject group (HEP, EPC, and
HEPEPC) and time (five time points for systemic and
four for regional). Effects and interaction were assessed at
the .05 levels of significance. Analysis of variance was con-
ducted with PROC MIXED in a statistical software, SAS,
version 8.2 (SAS Institute, Inc, Cary, NC).
RESULTS
Subjects and procedures. Forty-four subjects partici-
pated in this study. Mean age, prevalence of atherosclerosis,
and frequencies of surgical procedures for each group are
summarized in the Table. There were no significant differ-
ences in age among the three groups (P  .82). The
prevalence of atherosclerosis was similar among the three
groups (P .99). Association between surgical procedures
Subject characteristics
HEP EPC HEP  EPC P value
No. of subjects 17 12 15
Age (y; mean  SEM) 66.6  1.7 68.2  1.3 67.1  1.9 .82†
Atherosclerosis* 11 (64.7%) 8 (66.7%) 10 (66.7%) .99‡
Surgical procedures .47‡
Aortic reconstructions 4 (23.5%) 4 (33.3%) 2 (13.4%)
Abdominal cancer procedures 11 (64.7%) 5 (41.7%) 8 (53.3%)
Colectomies 10 4 7
Esophagectomies 0 1 1
Whipple procedures 1 0 0
Miscellaneous laparotomies 2 (11.8%) 3 (25.0%) 5 (33.3%)
*Atherosclerosis was defined as patient-reported history of coronary artery disease, myocardial infarction, or peripheral arterial occlusive disease, electrocar-
diographic evidence of CAD, or revascularization for CAD, peripheral arterial occlusive disease, or carotid artery disease.
†One-way analysis of variance.
‡Fisher exact test.
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and the patient groups was not significant (P  .47); the
frequencies of aortic reconstructions were similar among
the groups, as were the frequencies of abdominal cancer
procedures and miscellaneous laparotomies. No subject
had signs or symptoms of venous thromboembolism de-
velop during the study. Venous duplex ultrasound scans
were performed on 90% of subjects after surgery; no prox-
imal DVT were identified.
Systemic uPA level (Fig 1). Preoperative systemic
uPA levels in the three groups were similar (HEP 0.41
0.10 ng/mL; EPC  0.47  0.05 ng/mL; HEPEPC 
0.56  0.10 ng/mL; P  .05). There were no statistically
significant differences among the three groups at any time
point after surgery (P  .23; P  .21 for group by time
interaction). Furthermore, there were no statistically signif-
icant differences within any of the groups at any point after
surgery relative to before surgery (P  .26).
Regional uPA level (Fig 2). For the regional samples
collected from the common femoral vein, preoperative
ANES values in the three groups were similar (HEP 
0.45  0.07 ng/mL; EPC  0.37  0.06 ng/mL;
HEPEPC  0.47  0.07 ng/mL; P  .05). There were
no statistically significant differences among the three
groups at any time point after surgery (P .81; P .49 for
group by time interaction), and also there were no statisti-
cally significant differences within any of the groups at any
point after surgery relative to ANES (P  .073).
DISCUSSION
It is well documented that EPC devices reduce lower
extremity venous stasis, increasing flow velocities in major
leg veins.3-6 Originally, they were also believed to enhance
endogenous fibrinolysis. This belief originated from studies
in which tourniquet-induced compression of arm veins
increased plasma fibrinolytic activity.22 Venous compres-
sion was thought to increase synthesis or secretion of
profibrinolytic factors from venous endothelium. The as-
sumption was made that because EPC devices also com-
press endothelium, they would enhance fibrinolysis. Early
data supported this belief,7,8,23,24 but more recent studies
in which specific fibrinolytic factors were measured have
produced conflicting results.9-13 Comerota et al9 observed
small but significant increases in systemic fibrinolysis (in-
creased tPA activity, decreased PAI-1 activity) in healthy
volunteer subjects undergoing pneumatic compression.
However, Christen et al10 found no changes in either tPA
or PAI-1 antigen levels measured from the antecubital vein
in healthy volunteers after pumping with a sequential leg
device or a foot pump. Kosir et al12 measured tPA and
PAI-1 levels in patients undergoing general surgical proce-
dures treated with either heparin or EPC devices. They
found increases in both measurements in patients treated
with both methods of DVT prophylaxis, making it difficult
to draw conclusions regarding the effects of EPC on fibri-
nolysis.12 Jacobs et al11 showed decreased PAI-1 antigen
levels in the inferior vena cava of healthy volunteers after a
4-hour compression period but no changes after a second
period of compression.
We previously investigated whether EPC devices en-
hance systemic fibrinolytic activity in patients undergoing
surgical procedures with measurement of tPA and PAI-1
activities in antecubital venous samples and were unable to
show statistically significant changes.13 In a later study, no
significant changes in tPA and PAI-1 activities were found
in regional blood samples collected from the femoral vein
of the lower extremity to which the EPC device was ap-
plied.25
The differences among these results may in part be
explained because some investigators measured tPA and
PAI-1 activities9 and others measured antigen levels.10-12
Differences between these studies and ours13,25 may have
resulted from the use of healthy volunteers versus surgical
patients. However, of the previous studies, only one un-
Fig 1. Systemic uPA levels (ng/mL) in three study groups at each
time point. HEP group received subcutaneous heparin injections
for DVT prophylaxis, EPC group received thigh-length EPC
devices, and HEPEPC received both. Time points included
preoperative (PREOP; 1 day before surgery), ANES (after induc-
tion of anesthesia but before surgical incision), and postoperative
days (PODs) 1, 3, and 5.
Fig 2. Regional uPA levels (ng/mL) in three study groups at
each time point. HEP group received subcutaneous heparin injec-
tions for DVT prophylaxis, EPC group received thigh-length EPC
devices, and HEPEPC received both. Time points included
preoperative (PREOP; 1 day before surgery), ANES (after induc-
tion of anesthesia but before surgical incision), and postoperative
days (PODs) 1, 3, and 5.
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equivocally showed a favorable effect of EPC devices on
tPA and PAI-1.9 Moreover, the changes reported (4%
increase in tPA activity; 13% decrease in PAI-1 activity) are
quite small, and the clinical significance is questionable. We
have concluded that EPC devices do not enhance fibrino-
lysis, at least as measured with tPA and PAI-1 activities.
Urokinase plasminogen activator is also capable of
cleaving inactive plasminogen to the active form plasmin.
uPA is widely present in connective tissue, particularly in
cells with a fibroblast-like morphology, but also in epithelial
cells and in monocytes/macrophages.26,27 The traditional
view has been that tPA functions predominantly in fibrino-
lysis and uPA is involved in tissue remodeling.14,15 How-
ever, in recent studies performed in animal models, uPA has
been shown to have an active, perhaps even predominant
role, in fibrinolysis. In a mouse model of endotoxin-in-
duced thrombosis, uPA expression correlated with fibrin
dissolution, but tPA expression did not.18 In a dog model
of endogenous fibrinolysis, lysis of pulmonary emboli was
attributed to uPA expression rather than tPA.16 In a model
of vena caval thrombosis in rats, lysis was more closely
associated with elevated uPA levels than tPA levels. In this
study, uPA was secreted by monocytes recruited into
thrombus. It was concluded that lysis of thrombus was
mediated primarily by fibrinolytic factors originating from
cellular infiltrates rather than from endothelial-derived fac-
tors.17
Studies addressing the role of uPA in human fibrinoly-
sis are scarce, but findings such as those previous have led
investigators to propose a more important role for uPA
than initially believed.28 Moreover, uPA increases human
fibrinolysis when the contact phase of coagulation (pathway
in the coagulation cascade activated when factor XII binds
to a negatively charged surface rather than a plasma pro-
tein) is activated.29,30 In recent studies, it was shown that
uPA responds to known human fibrinolytic activators in a
similar fashion to tPA. Single bouts of strenuous physical
exercise and endurance training increase uPA and tPA levels
in parallel.20 Clearly, the role of uPA in human fibrinolysis
requires further investigation.
In this study, we investigated the effect of EPC on
systemic and regional uPA levels. We were unable to show
any statistically significant changes in either systemic or
regional uPA levels in either of the groups treated with EPC
devices compared with the group treated only with heparin.
The assay used in this study measures total protein, or
antigen, levels of uPA in plasma, including both unbound
uPA and that which is complexed to inhibitors.31 It is
possible that EPC devices increase levels of free uPA with-
out changing total antigen levels and that this effect was
missed in our study. However, available data suggest that
enhancement of fibrinolysis by uPA involves increases in
total antigen levels20; if pneumatic compression produces a
similar effect, measurements of uPA antigen should reflect
this. It is also possible that, as noted by Northeast et al,17
uPA is activated only when thrombus is present. In the
presence of DVT, EPC devices might activate uPA, result-
ing in thrombus breakdown. In this study, however, no
subject had ultrasound scan evidence of major DVT de-
velop; hence, no activation of uPA was observed. This is a
limitation of this study. Further investigation of uPA regu-
lation in the presence of DVT will be necessary before
additional conclusions regarding its role can be drawn.
Although enhancement of fibrinolysis with EPC de-
vices remains unclear, they may affect other pathways in the
postoperative procoagulant state. Chouhan et al32 showed
increased levels of tissue factor pathway inhibitor in healthy
volunteers treated with EPC devices. No studies to date
have addressed potential effects of EPC devices on postop-
erative platelet activity or the protein C system. At this time,
however, the only well-documented action of EPC devices
is enhancement of lower extremity blood flow. Our find-
ings suggest that prudent and safe use of these devices
requires that they be used in a manner that ensures that
increased flow and reduced stasis occur.
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